The Lannebo Health and New Technology fund declined by 5.1 percent in January, underperforming its benchmark index, which fell by 1.7 percent. Over the past 12 months, the fund has decreased by 13.6 percent, also lagging behind the index, which dropped by 1.3 percent. This information comes from a monthly report by fund managers Viktor Elmsjö and Stefan Kopperud.

The managers note that the month was marked by volatility after the President of the United States threatened to impose new tariffs on Europe as a means to force negotiations regarding Greenland.

"After the president backed away from his most aggressive rhetoric, the stock market rebounded. The Danish market showed the strongest performance in the Nordic region, and once again, small companies underperformed large companies," the managers write.

Positive contributors to the fund during the month included Xvivo Perfusion, Camurus, and Bioarctic.

On the negative side, Bico and Raysearch both performed weakly despite no significant news.

The largest holdings in the fund's portfolio at the end of the month were Camurus, Carasent, and H Lundbeck, with weights of 6.3, 5.1, and 4.8 percent, respectively.

Lannebo Health and New Technology, %January, 2026
Fund MoM, change in percent-5.1
Index MoM, change in percent-1.7
Fund one year, change in percent-13.6
Index one year, change in percent-1.3